v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended 9 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Mar. 31, 2026
Mar. 31, 2025
Income Statement [Abstract]        
Revenue $ 0 $ 0 $ 0 $ 0
Operating expenses:        
General and administrative (including stock-based compensation) 304,554 474,892 1,048,703 1,770,545
Depreciation 0 205 0 695
Research and development (including stock-based compensation) 3,137 5,778 17,959 19,389
Total operating expenses 307,691 480,875 1,066,662 1,790,629
Loss from operations (307,691) (480,875) (1,066,662) (1,790,629)
Other (income) expense:        
Interest income (40) (16) (74) (48)
Interest expense 118,433 34,542 295,946 270,809
Gain on disposal of assets 0 (4,245) 0 (4,245)
Other income (2,500) 0 (2,500) 0
Total other expense 115,893 30,281 293,372 266,516
Net (loss) (423,584) (511,156) (1,360,034) (2,057,145)
Net (loss) attributable to the noncontrolling interest 0 0 0 0
Net (loss) applicable to Bion's common stockholders $ (423,584) $ (511,156) $ (1,360,034) $ (2,057,145)
Net (loss) applicable to Bion's common stockholders per basic common share $ (0.01) $ (0.01) $ (0.02) $ (0.04)
Net (loss) applicable to Bion's common stockholders per diluted common share $ (0.01) $ (0.01) $ (0.02) $ (0.04)
Weighted-average number of common shares outstanding:        
Weighted-average number of common shares outstanding, Basic 57,304,600 56,597,169 56,943,370 56,553,015
Weighted-average number of common shares outstanding Diluted 57,304,600 56,597,169 56,943,370 56,553,015